AU2018362010B2 - Azabicyclo and diazepine derivatives for treating ocular disorders - Google Patents

Azabicyclo and diazepine derivatives for treating ocular disorders Download PDF

Info

Publication number
AU2018362010B2
AU2018362010B2 AU2018362010A AU2018362010A AU2018362010B2 AU 2018362010 B2 AU2018362010 B2 AU 2018362010B2 AU 2018362010 A AU2018362010 A AU 2018362010A AU 2018362010 A AU2018362010 A AU 2018362010A AU 2018362010 B2 AU2018362010 B2 AU 2018362010B2
Authority
AU
Australia
Prior art keywords
unsubstituted
methyl
branched
mmol
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018362010A
Other languages
English (en)
Other versions
AU2018362010A1 (en
Inventor
David Ellis
Howard Allen Ketelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2018362010A1 publication Critical patent/AU2018362010A1/en
Application granted granted Critical
Publication of AU2018362010B2 publication Critical patent/AU2018362010B2/en
Priority to AU2021205100A priority Critical patent/AU2021205100B2/en
Priority to AU2023202036A priority patent/AU2023202036B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018362010A 2017-11-03 2018-11-02 Azabicyclo and diazepine derivatives for treating ocular disorders Active AU2018362010B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021205100A AU2021205100B2 (en) 2017-11-03 2021-07-16 Azabicyclo and diazepine derivatives for treating ocular disorders
AU2023202036A AU2023202036B2 (en) 2017-11-03 2023-04-03 Azabicyclo and diazepine derivatives for treating ocular disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581073P 2017-11-03 2017-11-03
US62/581,073 2017-11-03
US201862749610P 2018-10-23 2018-10-23
US62/749,610 2018-10-23
PCT/IB2018/058631 WO2019087146A1 (en) 2017-11-03 2018-11-02 Azabicyclo and diazepine derivatives for treating ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021205100A Division AU2021205100B2 (en) 2017-11-03 2021-07-16 Azabicyclo and diazepine derivatives for treating ocular disorders

Publications (2)

Publication Number Publication Date
AU2018362010A1 AU2018362010A1 (en) 2020-04-09
AU2018362010B2 true AU2018362010B2 (en) 2021-05-13

Family

ID=64267873

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018362010A Active AU2018362010B2 (en) 2017-11-03 2018-11-02 Azabicyclo and diazepine derivatives for treating ocular disorders
AU2021205100A Active AU2021205100B2 (en) 2017-11-03 2021-07-16 Azabicyclo and diazepine derivatives for treating ocular disorders
AU2023202036A Active AU2023202036B2 (en) 2017-11-03 2023-04-03 Azabicyclo and diazepine derivatives for treating ocular disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021205100A Active AU2021205100B2 (en) 2017-11-03 2021-07-16 Azabicyclo and diazepine derivatives for treating ocular disorders
AU2023202036A Active AU2023202036B2 (en) 2017-11-03 2023-04-03 Azabicyclo and diazepine derivatives for treating ocular disorders

Country Status (12)

Country Link
US (3) US11306090B2 (https=)
EP (1) EP3704117B1 (https=)
JP (3) JP7065180B2 (https=)
KR (1) KR20200083976A (https=)
CN (1) CN111247147B (https=)
AU (3) AU2018362010B2 (https=)
BR (1) BR112020007744A2 (https=)
CA (2) CA3205816A1 (https=)
MX (2) MX2020004580A (https=)
SG (1) SG11202002692XA (https=)
TW (2) TWI826399B (https=)
WO (2) WO2019087149A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7665519B2 (ja) * 2019-02-01 2025-04-21 アルコン インコーポレイティド 近視を治療するための化合物、組成物及び医薬組成物
US12527739B2 (en) 2022-09-11 2026-01-20 Alcon Inc. Aqueous pharmaceutical compositions comprising benzyl atropine and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB979680A (en) * 1961-11-21 1965-01-06 Schwarz Arzneimittelfabrik G M Pharmaceutical compositions containing esters of quaternary atropinium salts
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB994493A (en) 1963-02-06 1965-06-10 Lepetit Spa Tropine derivative
DE1670177A1 (de) 1966-12-28 1970-11-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N-substituierten Noratropiniumsalzen
US5223528A (en) 1986-03-17 1993-06-29 University Of Florida Anticholinergic compounds, composititons and methods of treatment
IL158904A0 (en) 2001-05-25 2004-05-12 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
FR2834511B1 (fr) 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
CN1546490A (zh) 2003-12-15 2004-11-17 常俊标 不对称双羟基托品类生物碱及其合成新方法和药物用途
CN1283639C (zh) 2004-06-08 2006-11-08 吴建梅 治疗近视眼的哌仑西平有机酸盐及其滴眼剂
PL2657234T3 (pl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Optycznie czynna pochodna diazabicyklooktanowa i sposób jej wytwarzania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB979680A (en) * 1961-11-21 1965-01-06 Schwarz Arzneimittelfabrik G M Pharmaceutical compositions containing esters of quaternary atropinium salts
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BERGER ET AL., "p-Fluorotropic Acid and p-Fluoroatropine", JOURNAL OF ORGANIC CHEMISTRY, 1957, vol. 22, pages 451 - 452 *
CAS registry number 1879015-57-2; Date entered STN 3 March 2016; 3-(methylamino)-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-propanamide *
CAS registry number 1948576-76-8; Date entered STN 10 July 2016; N-[1-methyl-3-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-3-oxopropyl]-cyclopentanecarboxamide *
CAS registry number 1948789-35-2; Date entered STN 10 July 2016; N-[1-methyl-3-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-3-oxopropyl]-cyclohexanecarboxamide *
CAS registry number 1954063-07-0; Date entered STN 18 July 2016; N-[1-methyl-3-[methyl(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-3-oxopropyl]-cyclopentanecarboxamide *
CAS registry number 1955059-09-2; Date entered STN 19 July 2016; N-[1-methyl-3-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-3-oxopropyl]-cyclohexanecarboxamide *
CAS registry number 2177309-74-7; Date entered STN 20 February 2018; 2,3-dihydroxy-3-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-butanamide *
CHUA W H ET AL, "Atropine for the Treatment of Childhood Myopia", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., 2006, vol. 113, no. 12, pages 2285 - 2291 *
DEI S BARTOLINI A et al., "Differential analgesic activity of the enantiomers of atropine derivatives does not correlate with their muscarinic subtype selectivity", Eur. J. Med. Chem, 1997, vol. 32, no. 7-8, pages 595 - 605 *
HUNT ET AL., "Preparation and characterization of the tropic acid esters of tropan-3beta-ol, granatan-3alpha-ol and granatan-3beta-ol", J. PHARM. PHARMAC., 1970, vol. 22, no. suppl., pages 29S - 33S *
JR POLLING ET AL., "Effectiveness study of atropine for progressive myopia in Europeans", EYE, 2016, vol. 30, pages 998 - 1004 *
MAFII AND BIANCHI, "Anticholinergic Activity of Tropine-alpha-Methyltropate", NATURE, (1960), vol. 185, pages 844 - 845 *
ROMEIKE ET AL., "The biogenesis of hysoscine in Datura Stramonium L.", TETRAHEDRON LETTERS, 1960, vol. 22, pages 1 - 4 *
TANG ET AL, "Human erythrocyte as a model for investigating muscarinic agonists and antagonists", GENERAL PHARMACOLOGY, vol. 22, no. 3, 1991, pages 485 - 490 *

Also Published As

Publication number Publication date
JP2022101654A (ja) 2022-07-06
TWI826399B (zh) 2023-12-21
JP7065180B2 (ja) 2022-05-11
WO2019087146A1 (en) 2019-05-09
US11884666B2 (en) 2024-01-30
US12247028B2 (en) 2025-03-11
AU2018362010A1 (en) 2020-04-09
EP3704117B1 (en) 2026-01-28
AU2021205100B2 (en) 2023-01-05
JP7777613B2 (ja) 2025-11-28
RU2020117733A (ru) 2021-12-03
AU2023202036B2 (en) 2024-08-08
JP2020536922A (ja) 2020-12-17
TWI852865B (zh) 2024-08-11
CN111247147B (zh) 2026-02-24
AU2021205100A1 (en) 2021-08-12
WO2019087149A1 (en) 2019-05-09
CA3076457A1 (en) 2019-05-09
TW202417440A (zh) 2024-05-01
TW201922731A (zh) 2019-06-16
MX2022011310A (es) 2022-10-07
JP2024041971A (ja) 2024-03-27
US11306090B2 (en) 2022-04-19
CN111247147A (zh) 2020-06-05
US20240132497A1 (en) 2024-04-25
US20220267328A1 (en) 2022-08-25
SG11202002692XA (en) 2020-05-28
EP3704117A1 (en) 2020-09-09
CA3205816A1 (en) 2019-05-09
KR20200083976A (ko) 2020-07-09
AU2023202036A1 (en) 2023-05-04
US20210179616A1 (en) 2021-06-17
CA3076457C (en) 2023-09-19
BR112020007744A2 (pt) 2020-10-13
MX2020004580A (es) 2020-12-03

Similar Documents

Publication Publication Date Title
JP7053900B2 (ja) Ｇｌｐ－１受容体アゴニストおよびその使用
US10738076B2 (en) Lanosterol prodrug compound and preparation method therefor and use thereof
TWI831350B (zh) 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)- 氧雜環丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羥基-2-(羥甲基)丙-2-胺鹽之固體形式
AU2023202036B2 (en) Azabicyclo and diazepine derivatives for treating ocular disorders
CA3166485A1 (en) Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
TW202346289A (zh) 作為ｇｌｐ—１ｒ促效劑的化合物
TW201927783A (zh) 顆粒體蛋白前體調節劑及其使用方法
US10487088B2 (en) Tricyclic compound serving as immunomodulator
US20180009820A1 (en) Imidazole derivative used as antiviral agent and use thereof in preparation of medicament
US20250100968A1 (en) Bicyclic-heterocycle derivatives and related uses
EP1440075B1 (fr) Nouveaux derives amides heteroaromatiques de 3beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique
KR20220024868A (ko) Rock단백질 키나아제 억제제인 이소퀴놀리논의 유도체 및 그 응용
TW202108147A (zh) 化學化合物
RU2795521C2 (ru) Азабициклические и диазепиновые производные для лечения офтальмологических нарушений
US8487091B2 (en) Substituted cyclopentanes having prostaglandin activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)